➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Medtronic
Boehringer Ingelheim
Dow
Johnson and Johnson

Last Updated: May 30, 2020

DrugPatentWatch Database Preview

Litigation Details for Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)

Docket   Start Trial Date Filed 2017-03-03
Court District Court, D. Delaware Date Terminated 2019-03-18
Cause 35:271 Patent Infringement Assigned To
Jury Demand None Referred To
Parties NOVO NORDISK A/S; NOVO NORDISK INC.; TEVA PHARMACEUTICALS USA, INC.
Patents 6,235,004; 6,268,343; 8,114,833; 8,846,618; 9,265,893; 9,968,659; RE41,956
Attorneys Brian P. Egan; Gregory Springsted; Jack B. Blumenfeld; Karen Elizabeth Keller; Leora Ben-Ami; Maryellen Noreika; Robert Hyberg; Thomas F. Fleming
Firms Morris, Nichols, Arsht & Tunnell; Shaw Keller LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc.

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)

Date Filed Document No. Description Snippet Link To Document
2017-03-03 1 Complaint United States Patent Nos. 6,268,343 (the “ʼ343 patent”), 8,114,833 (the “ʼ833 patent”), 8,846,618 (the… COUNT FOR INFRINGEMENT OF U.S. PATENT NO. 6,268,343 19. Novo Nordisk re-alleges…(the “ʼ618 patent”), 9,265,893 (the “ʼ893 patent”), and RE41,956 (the “RE ʼ956 patent”), which cover,… 1. This is an action for patent infringement under the patent laws of the United States, Title… THE PATENTS-IN-SUIT 5. On July 31, 2001, the United States Patent and Trademark External link to document
2019-03-18 101 Judgment - Consent .S. Patent Nos. 6,268,343 (the "'343 patent"), 8,114,833 (the '"833 patent"…,618 (the '"618 patent"), 9,265,893 (the "'893 patent"), , and RE41,956 (…enjoined until expiration of US Patent 9,968,659 ("the '659 patent") and the '343, '… (the "RE '956 patent"} asserted against Teva, are not held invalid or unenforceable, absent… '833, '618, '893, and RE '956 Patents would be infringed by any unlicensed manufacture External link to document
2017-03-03 4 Patent/Trademark Report to Commissioner the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,268,343 B1; 8,114,833 B2; 8,846,618…2017 18 March 2019 1:17-cv-00227 830 Patent None District Court, D. Delaware External link to document
2018-06-26 61 Report and Recommendations ., 1:24-26 ("U.S. Pat. No. 6,235,004 [("the '004 patent")] discloses an injection device….S. Patent Nos. 6,268,343 ("the '343 patent"); 8,114,833 ("the '833 patent"…(EP '581 patent at 17), as do similar figures in the '004 patent, '004 patent, figs. 15-16…the '004 patent. '893 patent, 1:29-34 (citing Figs. 15-16 of the '004 patent) ("[T]he….S. Patent Nos. 8,114,833 ("the '833 patent"); 9,265,893 ("the '893 patent" External link to document
2018-07-30 65 Notice of Service Infringement of Claims 1, 2, 3, and 14 of U.S. Patent No. 6,268,343 by Teva Pharmaceuticals USA, Inc.; (7) Opening…Regarding Infringement of Claim 39 of U.S. Patent No. 6,268,343 by Teva Pharmaceuticals USA, Inc.; and (…Charles E. Clemens Regarding Infringement of U.S. Patent Nos. 9,265,893 and RE 41,956; (2) Opening Expert…Expert Report of Peter M. Tessier, Ph.D. Regarding Patent Infringement by Teva Pharmaceuticals USA, Inc.;…2017 18 March 2019 1:17-cv-00227 830 Patent None District Court, D. Delaware External link to document
2018-07-30 66 Notice of Service , MSME, PE Regarding Invalidity of U.S. Patent Nos. 9,265,893 and RE41,956; and 3. Opening Expert Report…2017 18 March 2019 1:17-cv-00227 830 Patent None District Court, D. Delaware External link to document
2018-09-10 70 , PE Regarding Non-Infringement of U.S. Patent Nos. 9,265,893 and RE41,956; and 3. Rebuttal Expert Report…2017 18 March 2019 1:17-cv-00227 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Dow
McKesson
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.